Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
13 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
KA-PHARMA from Sint-Jans-Molenbeek, company number BE1005869016, closed financial year 2025 with a result of € 48,527 after tax. For that financial year KA-PHARMA recorded a gross margin of € 50,690 and equity of € 157,474. Compared with financial year 2024, the result moved from € 105,946 to € 48,527. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ 157,474
▲ 45% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 48,527
▼ 54% vs 2024
Profit after tax over the fiscal year.
€ 78,133
▲ 256% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 154,474.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 1,315
▲ € 1,239 vs 2024
No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.
€ 691
▼ 33% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,156
▲ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,334
▼ 22% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 106,679 | € 50,690 | ▼ 52% |
| Profit after taxes | € 105,946 | € 48,527 | ▼ 54% |
| Equity | € 108,946 | € 157,474 | ▲ 45% |
| Total debts | € 8,512 | € 7,490 | ▼ 12% |
| Cash | € 21,976 | € 78,133 | ▲ 256% |
| Retained profit | € 105,946 | € 154,474 | ▲ 46% |
| Balance sheet total | € 117,458 | € 164,964 | ▲ 40% |
Key figures of KA-PHARMA, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KA-PHARMA?
What happened at KA-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 48,527 (▼ 54% vs 2024). Source: NBB ↗
- New establishment in Sint-Jans-Molenbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 105,946 profit in 2024 to € 48,527 profit in 2025.
Best year ever: 2024, with € 105,946 profit.
Management
Behind KA-PHARMA is Aurore-Espérance Kaneza.
Directors
According to the 2025 annual accounts
Aurore-Espérance Kaneza
Director
Establishments
Establishment units
Physical locations of this company
Joseph Baecklaan 74 box 26
1080 Sint-Jans-Molenbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
All companies at this address →Urro
€ 231,102 gross margin · 2025
SWIFT LINE
€ 148,258 gross margin · 2025
A.L.S. Management
€ 25,096 gross margin · 2024
CANDARO INVEST
€ 106,343 revenue · 2022
SERVICES ONLINE
+8 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1005.869.016
- VAT number
- BE 1005.869.016
- Registered office
- Joseph Baecklaan 74 bus 26, 1080 Sint-Jans-Molenbeek
- Names & denominations
- KA-PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 February 2024
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Overige zakelijke dienstverlening, neg